Shoklo Malaria Research Unit, 68/30 Bantung Road, P.O. Box 46, Mae Sot, Tak 63110, Thailand.
Antimicrob Agents Chemother. 2011 Sep;55(9):4338-42. doi: 10.1128/AAC.00154-11. Epub 2011 Jun 27.
In order to study the pharmacokinetic properties of amodiaquine and desethylamodiaquine during pregnancy, 24 pregnant women in the second and third trimesters of pregnancy and with Plasmodium vivax malaria were treated with amodiaquine (10 mg/kg of body weight/day) for 3 days. The same women were studied again at 3 months postpartum. Plasma was analyzed for amodiaquine and desethylamodiaquine by use of a liquid chromatography-tandem mass spectrometry method. Individual concentration-time data were evaluated using noncompartmental analysis. There were no clinically relevant differences in the pharmacokinetics of amodiaquine and desethylamodiaquine between pregnant (n = 24) and postpartum (n = 18) women. The results suggest that the current amodiaquine dosing regimen is adequate for the treatment of P. vivax infections during pregnancy.
为了研究妊娠期间阿莫地喹和去乙基阿莫地喹的药代动力学特性，对 24 名处于妊娠第二和第三阶段且患有间日疟的孕妇采用阿莫地喹（10mg/kg 体重/天）进行 3 天治疗。这些女性在产后 3 个月时再次接受研究。采用液相色谱-串联质谱法分析阿莫地喹和去乙基阿莫地喹的血浆浓度。采用非房室分析方法评估个体浓度-时间数据。妊娠（n=24）和产后（n=18）妇女的阿莫地喹和去乙基阿莫地喹药代动力学无临床相关差异。结果表明，目前的阿莫地喹给药方案足以治疗妊娠期间的间日疟感染。
